NEW YORK (GenomeWeb) – German multiomics tools firm Centogene announced today a collaboration with the medical faculties of the Universities of Greifswald and Rostock to develop diagnostic tools for personalized, immune-based treatments for colon and pancreatic tumors.
As part of the research project, Centogene will genetically profile cancer patients to identify immune-relevant mutations and identify specific biomarkers for early differential diagnosis and therapy monitoring.